Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis

Journal of Pediatric Endocrinology and Metabolism

Volumn 22, Issue 1, 2009, Pages 55-63

  Brown, Justin J ^a,b,c   Zacharin, M R ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Bisphosphonate; Children; Osteogenesis imperfecta; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE PAIN; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; HUMAN; LUMBAR SPINE; OBSERVATIONAL STUDY; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; SCORING SYSTEM; TREATMENT DURATION;

EID: 61849099801     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2009.22.1.55     Document Type: Article

References (34)

1. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 2004; 17: 1511-1517.
2. Russell RG. Bisphosphonates: from bench to bedside. Ann NY Acad Sci 2006; 1068: 367-401.
3. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85: 456-461.
4. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-1487.
5. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates' interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991; 49: 407-415.
6. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-1480.
7. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20: 1235-1243.
8. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 2003; 39: 88-92.
9. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005; 90: 494-499.
10. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-1385.
11. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42_446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
12. Högler W, Yap F, Little DG, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004; 145: 701-704.
13. Van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy X-ray absorptiometry in white children and young adults. Arch Dis Child 2002; 87: 341-347.
14. Ward KA, Ashby RL, Roberts SA, Adams JE, Zulf Mughal M. UK reference data for the Hologic QDR Discovery dual-energy X ray absorptiometry scanner in healthy children and young adults aged 6-17 years. Arch Dis Child 2007; 92: 53-59.
15. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R, Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
16. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-1850.
17. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-644.
18. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-364,
19. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta; lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15: 163-174.
20. Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002; 87: 562-563.
21. Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta: open-label study in seven patients. Joint Bone Spine 2002; 69: 486-490.
22. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-614.
23. Falk M J, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-578.
24. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003; 92: 452-455.
25. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-986.
26. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 786-791.
27. Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18: 43-53.
28. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363: 1427-1431.
29. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-763.
30. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006; 91: 1268-1274.
31. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91: 511-516.
32. Thompson K, Rogers MJ. Perspectives: Bisphosphonates and γδ T-cells: New Insights into Old Drugs. BoneKEy-Osteovision 2006; 3: 5-13. www.bonekeyibms.org/cgi/content/full/ibmske;3/8/5.
33. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007; 74: 32-38.
34. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics 2003; 111: 1030-1036.